- Home
- DAWN
DAWN
Day One Biopharmaceuticals Inc.
as 04-18-2025 1:34pm EST
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $32.29 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.41 - $18.07 | Next Earning Date: | 05-05-2025 |
| Revenue: | $131,161,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 25.78% | Revenue Growth (next year): | 68.37% |
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dubow Adam | DAWN | GENERAL COUNSEL | Feb 15 '25 | Sell | $11.96 | 4,646 | $55,580.10 | 39,602 | |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | Feb 15 '25 | Sell | $11.96 | 12,048 | $144,130.22 | 128,015 | |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | Feb 15 '25 | Sell | $11.96 | 4,370 | $52,278.31 | 252,638 |
Latest Day One Biopharmaceuticals Inc. News
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
BofA Adjusts Price Target on Day One Biopharmaceuticals to $21 From $24, Keeps Buy Rating
Simply Wall St.
10 days ago
Exploring US High Growth Tech Stocks This April 2025
Insider Monkey
10 days ago
Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple
WWD
a month ago
EXCLUSIVE: Plant Medicine Brand Apothékary Is Taking Customers on a $10,000 Immersive Trip to Japan
Simply Wall St.
a month ago
High Growth Tech Stocks In The US With Promising Potential
Insider Monkey
a month ago
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory
Zacks
2 months ago
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Zacks
2 months ago
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Compare DAWN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.